High production of enantiopure (R,R)-2,3-butanediol from crude glycerol by Klebsiella pneumoniae with an engineered oxidative pathway and a two-stage agitation strategy
Microbial Cell Factories · 2024
DOI: 10.1186/s12934-024-02480-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Cell Factories, 2024. Verfasst von Min-Ho Jo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Microbial Biotechnology Research Center, Jeonbuk Branch Institute, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongeup, Jeonbu…. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Glycerol, Butylene Glycols, Fermentation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
( R,R )-2,3-butanediol (BDO) is employed in a variety of applications and is gaining prominence due to its unique physicochemical features. The use of glycerol as a carbon source for 2,3-BDO production in Klebsiella pneumoniae has been limited, since 1,3-propanediol (PDO) is generated during glycerol fermentation.
Results
In this study, the inactivation of the budC gene in K. pneumoniae increased the production rate of ( R,R )-2,3-BDO from 21.92 ± 2.10 to 92.05 ± 1.20%. The major isomer form of K. pneumoniae ( meso -2,3-BDO) was shifted to ( R,R )-2,3-BDO. The purity of ( R,R )-2,3-BDO was examined by agitation speed, and 98.54% of ( R,R )-2,3-BDO was obtained at 500 rpm. However, as the cultivation period got longer, the purity of ( R,R )-2,3-BDO declined. For this problem, a two-step agitation speed control strategy (adjusted from 500 to 400 rpm after 24 h) and over-expression of the dhaD gene involved in ( R,R )-2,3-BDO biosynthesis were used. Nevertheless, the purity of ( R,R )-2,3-BDO still gradually decreased over time. Finally, when pure glycerol was replaced with crude glycerol, the titer of 89.47 g/L of ( R,R )-2,3-BDO (1.69 g/L of meso -2,3-BDO), productivity of 1.24 g/L/h, and yield of 0.35 g/g consumed crude glycerol was achieved while maintaining a purity of 98% or higher.
Conclusions
This study is meaningful in that it demonstrated the highest production and productivity among studies in that produced ( R,R )-2,3-BDO with a high purity in Klebsiella sp. strains. In addition, to the best of our knowledge, this is the first study to produce ( R,R )-2,3-BDO using glycerol as the sole carbon source.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbial Biotechnology Research Center, Jeonbuk Branch Institute, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongeup, Jeonbuk, 56212, Republic of Korea.
- Department of Chemical and Biomolecular Engineering and Institute for the BioCentury, KAIST, Daejeon, 34141, Republic of Korea.
- Microbial Biotechnology Research Center, Jeonbuk Branch Institute, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongeup, Jeonbuk, 56212, Republic of Korea. baekrock.oh@kribb.re.kr.
Zitieren
APA
Jo, M. H., Ju, J. H., Heo, S. Y., Son, C. B., Jeong, K. J., & Oh, B. R. (2024). High production of enantiopure (R,R)-2,3-butanediol from crude glycerol by Klebsiella pneumoniae with an engineered oxidative pathway and a two-stage agitation strategy. Microbial Cell Factories. https://doi.org/10.1186/s12934-024-02480-4
Vancouver
Jo MH, Ju JH, Heo SY, Son CB, Jeong KJ, Oh BR. High production of enantiopure (R,R)-2,3-butanediol from crude glycerol by Klebsiella pneumoniae with an engineered oxidative pathway and a two-stage agitation strategy. Microbial Cell Factories. 2024. doi:10.1186/s12934-024-02480-4
BibTeX
@article{Jo2024,
author = {Jo, Min-Ho and Ju, Jung-Hyun and Heo, Sun-Yeon and Son, Chang-Bum and Jeong, Ki Jun and Oh, Baek-Rock},
title = {High production of enantiopure (R,R)-2,3-butanediol from crude glycerol by Klebsiella pneumoniae with an engineered oxidative pathway and a two-stage agitation strategy},
journal = {Microbial Cell Factories},
year = {2024},
doi = {10.1186/s12934-024-02480-4}
}
EUVIMED